July 8, 2016Open Access

Clozapinev. first- and second-generation antipsychotics in treatment-refractory schizophrenia: systematic review and meta-analysis

Key Points

Key points are not available for this paper at this time.

Abstract

Clozapine is superior for treatment-refractory disorder but if there is no response by 6 months medications with lower adverse reactions should be considered.

Bookmark

View Full Paper

Cite This Study

Siskind et al. (Fri,) studied this question.

synapsesocial.com/papers/69d820fb617ce96c42ae30ba https://doi.org/https://doi.org/10.1192/bjp.bp.115.177261

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Preferred reporting items for systematic reviews and meta-analyses: the PRISMA Statement.2009 · 45,128 citations
2A double-blind comparative study of clozapine versus chlorpromazine on Chinese patients with treatment-refractory schizophrenia1997 · 61 citations
3Pharmaceutical industry sponsorship and research outcome and quality: systematic review2003 · 2,162 citations
4Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement2009 · 63,996 citations
5Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement2009 · 83,240 citations

Bookmark

View Full Paper